All the news Showing 10 of 19 articles from: CirrhosisGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Maviret cures most people with HCV genotype 3 and those with cirrhosis Liz Highleyman / 24 October 2017 Glecaprevir and pibrentasvir, the two drugs in the recently approved Maviret co-formulation, demonstrated high sustained response rates for people with chronic hepatitis C virus (HCV) genotype 3 and for people with liver ... HCV treatment allows one in four people to come off the transplant waiting list Keith Alcorn / 24 April 2017 Around one in four people with hepatitis C and decompensated cirrhosis came off the transplant waiting list in Europe after direct-acting antiviral treatment, and very few had any subsequent liver-related ... Curing hepatitis C may help reduce kidney disease progression Liz Highleyman / 20 December 2016 People who achieved sustained virological response to interferon-based hepatitis C treatment experienced significantly less decline in kidney function, especially if they had liver cirrhosis, according to study findings presented at the 2016 AASLD ... Liver fibrosis improves after successful treatment for hepatitis C Liz Highleyman / 02 December 2015 A majority of people with chronic hepatitis C and advanced fibrosis or cirrhosis showed improvement in liver health following treatment, according to study findings presented last week at the 2015 AASLD Liver ... Liver function and survival improve after treatment with Viekirax + Exviera regimen Liz Highleyman / 27 June 2015 People with hepatitis C who were treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival compared to ... Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients Keith Alcorn / 13 May 2015 Shortening hepatitis C treatment to 6 weeks for easier-to-treat patients without cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with genotype 1 infection, according to results of a ... Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis Liz Highleyman / 06 May 2015 Interferon-free regimens containing sofosbuvir (Sovaldi) plus simeprevir (Olysio) cured about three-quarters of people with genotype 1 chronic hepatitis C with advanced cirrhosis and MELD scores >10 in the real-world HCV-TARGET study, researchers reported ... Sofosbuvir/ledipasvir cures most previously treated hepatitis C patients with cirrhosis Liz Highleyman / 07 January 2015 Difficult-to-treat hepatitis C patients with liver cirrhosis who were not cured with a prior course of first-generation HCV protease inhibitors had a sustained response rate of 96-97% when re-treated with sofosbuvir/ledipasvir with ribavirin ... Sofosbuvir for hepatitis C works well despite multiple negative predictive factors Liz Highleyman / 24 April 2014 Hepatitis C treatment using sofosbuvir (Sovaldi) is highly effective even for people with multiple factors traditionally associated with poor response. Having four or more negative predictive factors, however, raises the risk of post-treatment relapse, ... MK-5172 + MK-8742 demonstrate good early post-treatment response rates Liz Highleyman / 24 April 2014 A combination of two direct-acting antivirals, MK-5172 and MK-8742, with or without ribavirin, led to early post-treatment sustained response rates above 90% for people with genotype 1 hepatitis C virus (HCV), including ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive